New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 14, 2014
09:35 EDTCBMGCellular Biomedicine reports Q2 EPS (85c) vs. (44c) last year
As of June 30, the company had $13.6M in cash and cash equivalents.
News For CBMG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 22, 2015
09:26 EDTCBMGCellular Biomedicine announces positive Phase I results from CAR-T CD30 trial
Cellular Biomedicine Group announced encouraging clinical data from its Chimeric Antigen Receptor, or CAR-T, CD30-positive Hodgkin's lymphoma immuno-oncology clinical development program. The results of this trial to date demonstrated that five out of seven patients responded to the treatment. CD30-directed CAR-T cell therapy was demonstrated in this trial to be safe, feasible and efficient. This trial was a Phase I, open-label trial whereby enrolled patients received escalating doses of autologous T cells transduced with a CD30-directed chimeric antigen receptor moiety for a consecutive 3-5 days. The level of CAR transgenes in peripheral blood and biopsied tumor tissues were measured periodically according to assigned protocol by Quantitative PCR.
May 18, 2015
06:13 EDTCBMGCellular Biomedicine reports Q1 EPS (39c), one estimate (40c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use